

# Michael R Bristow

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6635399/publications.pdf>

Version: 2024-02-01

74  
papers

9,954  
citations

147801  
31  
h-index

95266  
68  
g-index

77  
all docs

77  
docs citations

77  
times ranked

8586  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure. <i>New England Journal of Medicine</i> , 2004, 350, 2140-2150.	27.0	5,193
2	$\beta$ -Adrenergic Receptor Blockade in Chronic Heart Failure. <i>Circulation</i> , 2000, 101, 558-569.	1.6	953
3	Myosin Heavy Chain Isoform Expression in the Failing and Nonfailing Human Heart. <i>Circulation Research</i> , 2000, 86, 386-390.	4.5	480
4	Myocardial Gene Expression in Dilated Cardiomyopathy Treated with Beta-Blocking Agents. <i>New England Journal of Medicine</i> , 2002, 346, 1357-1365.	27.0	462
5	Increased Angiotensin-(1-7) Forming Activity in Failing Human Heart Ventricles. <i>Circulation</i> , 2003, 108, 1707-1712.	1.6	305
6	Myocardial-Directed Overexpression of the Human $\beta$ -Adrenergic Receptor in Transgenic Mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2000, 32, 817-830.	1.9	239
7	COVID-19 and Cardiovascular Disease. <i>Circulation Research</i> , 2021, 128, 1214-1236.	4.5	232
8	Cardiovascular Drug Development. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1567-1582.	2.8	168
9	Transcriptome analysis of human heart failure reveals dysregulated cell adhesion in dilated cardiomyopathy and activated immune pathways in ischemic heart failure. <i>BMC Genomics</i> , 2018, 19, 812.	2.8	150
10	Treatment of Chronic Heart Failure With $\beta$ -Adrenergic Receptor Antagonists. <i>Circulation Research</i> , 2011, 109, 1176-1194.	4.5	147
11	Filamin C Truncation Mutations Are Associated With Arrhythmogenic Dilated Cardiomyopathy and Changes in the Cell-Cell Adhesion Structures. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 504-514.	3.2	125
12	Angiotensin-(1-7) Formation in the Intact Human Heart. <i>Circulation</i> , 2003, 108, 1679-1681.	1.6	114
13	An $\beta$ -Adrenergic Receptor Polymorphism Alters the Norepinephrine-Lowering Effects and Therapeutic Response of the $\beta$ -Blocker Bucindolol in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2010, 3, 21-28.	3.9	103
14	The role of third-generation beta-blocking agents in chronic heart failure. <i>Clinical Cardiology</i> , 1998, 21, 13-113.	1.8	85
15	Selective versus nonselective $\beta$ -blockade for heart failure therapy: are there lessons to be learned from the COMET trial?. <i>Journal of Cardiac Failure</i> , 2003, 9, 444-453.	1.7	72
16	Tumor Necrosis Factor- $\alpha$ and Cardiomyopathy. <i>Circulation</i> , 1998, 97, 1340-1341.	1.6	60
17	Association of Variants in <i>BAG3</i> With Cardiomyopathy Outcomes in African American Individuals. <i>JAMA Cardiology</i> , 2018, 3, 929.	6.1	57
18	Histamine H <sub>2</sub> Receptor Antagonists, Left Ventricular Morphology, and Heart Failure Risk. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1544-1552.	2.8	54

#	ARTICLE	IF	CITATIONS
19	Structural and Functional Phenotyping of the Failing Heart. <i>JACC: Heart Failure</i> , 2017, 5, 772-781.	4.1	53
20	Dynamic Regulation of SARS-Cov-2 Binding and Cell Entry Mechanisms in Remodeled Human Ventricular Myocardium. <i>JACC Basic To Translational Science</i> , 2020, 5, 871-883.	4.1	51
21	What Type of $\beta$ -Blocker Should Be Used to Treat Chronic Heart Failure?. <i>Circulation</i> , 2000, 102, 484-486.	1.6	50
22	Detection and Management of Geographic Disparities in the TOPCAT Trial. <i>JACC Basic To Translational Science</i> , 2016, 1, 180-189.	4.1	50
23	Prevention of Atrial Fibrillation by Bucindolol Is Dependent on the Beta 1 389 Arg/Gly Adrenergic Receptor Polymorphism. <i>JACC: Heart Failure</i> , 2013, 1, 338-344.	4.1	43
24	lncExACT1 and DCHS2 Regulate Physiological and Pathological Cardiac Growth. <i>Circulation</i> , 2022, 145, 1218-1233.	1.6	43
25	Myocardial microRNAs associated with reverse remodeling in human heart failure. <i>JCI Insight</i> , 2017, 2, e89169.	5.0	42
26	Therapeutic Molecular Phenotype of $\beta$ -Blocker-Associated Reverse-Remodeling in Nonischemic Dilated Cardiomyopathy. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 270-283.	5.1	40
27	Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving $\beta$ -blocking agents. <i>Current Cardiology Reports</i> , 2001, 3, 224-231.	2.9	37
28	New-onset Atrial Fibrillation Predicts Heart Failure Progression. <i>American Journal of Medicine</i> , 2014, 127, 963-971.	1.5	36
29	Congestive Heart Failure: Fifty Years of Progress. <i>Circulation</i> , 2000, 102, .	1.6	36
30	Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. <i>European Journal of Heart Failure</i> , 2013, 15, 324-333.	7.1	33
31	Race, Common Genetic Variation, and Therapeutic Response Disparities in Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 561-572.	4.1	33
32	Maturation of Pluripotent Stem Cell-Derived Cardiomyocytes Enables Modeling of Human Hypertrophic Cardiomyopathy. <i>Stem Cell Reports</i> , 2021, 16, 519-533.	4.8	33
33	Second- and third-generation beta-blocking drugs in chronic heart failure. <i>Cardiovascular Drugs and Therapy</i> , 1997, 11, 291-296.	2.6	30
34	Visual analysis of biological data-knowledge networks. <i>BMC Bioinformatics</i> , 2015, 16, 135.	2.6	29
35	Serial Gene Expression Profiling in the Intact Human Heart. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 579-588.	0.6	28
36	Outcomes of cardiac resynchronization therapy in patients with intermittent atrial fibrillation or atrial flutter in the COMPANION trial. <i>Heart Rhythm</i> , 2017, 14, 858-865.	0.7	26

#	ARTICLE	IF	CITATIONS
37	Cellular and molecular remodeling in a heart failure model treated with the $\beta^2$ -blocker carteolol. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 276, H1678-H1690.	3.2	22
38	Sex-related differences in age-associated downregulation of human ventricular myocardial $\beta^1$ -adrenergic receptors. Journal of Heart and Lung Transplantation, 2016, 35, 352-361.	0.6	20
39	Temporal analysis of mRNA and miRNA expression in transgenic mice overexpressing Arg- and Gly389 polymorphic variants of the $\beta^1$ -adrenergic receptor. Physiological Genomics, 2011, 43, 1294-1306.	2.3	17
40	Transcriptome signature of ventricular arrhythmia in dilated cardiomyopathy reveals increased fibrosis and activated TP53. Journal of Molecular and Cellular Cardiology, 2020, 139, 124-134.	1.9	17
41	The Adrenergic System in Pulmonary Arterial Hypertension: Bench to Bedside (2013 Grover Conference) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	1.7	16
42	Pharmacogenetic targeting of drugs for heart failure. , 2012, 134, 107-115.		14
43	Lessons Learned and Insights Gained in the Design, Analysis, and Outcomes of the COMPANION Trial. JACC: Heart Failure, 2016, 4, 521-535.	4.1	14
44	Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT. European Journal of Heart Failure, 2017, 19, 457-465.	7.1	14
45	Histamine H2 Receptor Polymorphisms, Myocardial Transcripts, and Heart Failure (from the Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	1.6	13
46	Integrated analysis of miRNA-mRNA interaction in pediatric dilated cardiomyopathy. Pediatric Research, 2022, 92, 98-108.	2.3	12
47	Activation of PDGFRA signaling contributes to filamin C-related arrhythmogenic cardiomyopathy. Science Advances, 2022, 8, eabk0052.	10.3	12
48	Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop. Circulation: Heart Failure, 2021, 14, .	3.9	11
49	Of Phospholamban, Mice, and Humans With Heart Failure. Circulation, 2001, 103, 787-788.	1.6	10
50	The Addition of a Defibrillator to Resynchronization Therapy Decreases Mortality in Patients With Nonischemic Cardiomyopathy. JACC: Heart Failure, 2021, 9, 439-449.	4.1	10
51	Sequential analysis of myocardial gene expression with phenotypic change: Use of cross-platform concordance to strengthen biologic relevance. PLoS ONE, 2019, 14, e0221519.	2.5	8
52	Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. American Heart Journal, 2022, 246, 136-143.	2.7	8
53	Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009591.	4.8	5
54	PEAX: INTERACTIVE VISUAL ANALYSIS AND EXPLORATION OF COMPLEX CLINICAL PHENOTYPE AND GENE EXPRESSION ASSOCIATION. , 2014, , .		4

#	ARTICLE	IF	CITATIONS
55	Heart Rate in Preserved Ejection Fraction Heart Failure. JACC: Heart Failure, 2017, 5, 792-794.	4.1	4
56	Changing the Research Culture in the United States. JACC: Heart Failure, 2018, 6, 344-345.	4.1	4
57	The Essential Vulnerability of Human Cardiac Myocytes to SARS-CoV-2. JACC Basic To Translational Science, 2021, 6, 346-349.	4.1	4
58	Angiotensin II Receptors in the Normal and Failing Heart. Heart Failure Reviews, 1999, 3, 199-208.	3.9	3
59	The COMET Trial. Congestive Heart Failure, 2005, 11, 39-47.	2.0	3
60	Treatment of the Heart Failure Patient With Atrial Fibrillation. JACC: Heart Failure, 2013, 1, 29-30.	4.1	3
61	Alterations in Myocardial Gene Expression as a Basis for Cardiomyopathies and Heart Failure. Novartis Foundation Symposium, 2008, , 73-89.	1.1	2
62	Impact of Degree of Left Ventricular Remodeling on Clinical Outcomes From Cardiac Resynchronization Therapy. JACC: Heart Failure, 2019, 7, 281-290.	4.1	2
63	The FDA Regulatory Process for Drug and Genetic Diagnostic Test Approvals. Clinical and Translational Science, 2008, 1, 188-189.	3.1	1
64	Polymorphic Variation in the G-Protein Beta-3 Subunit Gene and Response to BiDil in A-HeFT. JACC: Heart Failure, 2014, 2, 558-560.	4.1	1
65	Fine Tuning Adenylyl Cyclase as a (Gene) Therapy for Heart Failure. JACC Basic To Translational Science, 2016, 1, 630-632.	4.1	1
66	Genetic variation expressed in the brain may impact heart failure. European Journal of Heart Failure, 2017, 19, 324-325.	7.1	1
67	Abstract 079: Nebivolol Associated With Reduced Incident Cardiovascular Events In Hypertensive Patients Compared With Non-vasodilatory Beta Blockers. Circulation, 2021, 143, .	1.6	1
68	Serum response factor deletion 5 regulates phospholamban phosphorylation and calcium uptake. Journal of Molecular and Cellular Cardiology, 2021, 159, 28-37.	1.9	1
69	An <i>LMNA</i> synonymous variant associated with severe dilated cardiomyopathy: Case report. American Journal of Medical Genetics, Part A, 2022, 188, 600-605.	1.2	1
70	Dynamic Regulation of SARS-CoV-2 Binding and Cell Entry Mechanisms in Remodeled Human Ventricular Myocardium. SSRN Electronic Journal, 0, , .	0.4	1
71	Cardiac Adrenergic Activation in Heart Failure With Preserved Ejection Fraction. JACC Basic To Translational Science, 2022, 7, 128-130.	4.1	1
72	Contractile reserve and the response to cardiac resynchronization therapy. International Journal of Cardiology, 2018, 252, 234-235.	1.7	0

#	ARTICLE	IF	CITATIONS
73	Entrepreneurialism in the Translational Biologic Sciences. JACC Basic To Translational Science, 2018, 3, 1-8.	4.1	0
74	MicroRNA expression in heart failure. FASEB Journal, 2012, 26, 336.3.	0.5	0